JournalArta
Wednesday, November 18, 2026 · JakartaS&P 7,340.53 ▼1.03%USD/IDR 18,245 ▼0.09%
JournalArta
Global Edition
beyond headlines
Advertisement

TriPRIL Therapy Shrinks Myeloma in 12 of 15 Patients

A first-in-human trial found that TriPRIL, a CAR T-cell therapy designed to recognize two proteins on myeloma cells, reduced or eliminated signs of cancer in 12 of 15 patients with relapsed or refractory multiple myeloma. Researchers plan a larger phase 2 trial.

By matthew jonathan
November 18, 20262 min read
TriPRIL Therapy Shrinks Myeloma in 12 of 15 Patients
TriPRIL Therapy Shrinks Myeloma in 12 of 15 Patients

Mass General Brigham Cancer Institute researchers found that the dual-target car therapy shows reduced or eliminated signs of multiple myeloma in 12 of 15 patients in a first-in-human trial.

The experimental treatment, called TriPRIL, targets two proteins on cancer cells rather than one. The early results offer a potential approach for patients whose myeloma returns after treatment, including those who have already received a CAR T-cell therapy aimed at one of the targets.

Eight patients, or 53%, had no signs of active myeloma in blood, urine and bone marrow tests, according to the study. The other responses brought the total number of patients whose cancer signs fell by at least half to 12, or 80%.

Advertisement

“TriPRIL adds TACI as a second target, allowing it to find and attack myeloma cells, even if they stop expressing BCMA,” said co-senior author Marcela V. Maus, director of the institute’s Cellular Immunotherapy Program.

Multiple myeloma is a cancer of plasma cells, immune cells that produce antibodies. CAR T-cell therapies modify a patient’s T cells to find and attack cancer cells.

Existing CAR T-cell therapies for myeloma target B-cell maturation antigen, or BCMA. TriPRIL also recognizes transmembrane activator and CAML interactor, or TACI. The researchers designed it using human proteins, which they believe may make the treatment less likely to trigger anti-drug antibodies that could reduce the persistence and effects of other CAR T cells.

Advertisement

The phase 1 trial treated 15 patients whose myeloma had returned despite many previous treatments. Nine had previously received a BCMA-directed CAR T-cell therapy, but their cancer progressed.

TriPRIL cells remained detectable in some patients’ blood more than six months after treatment. Researchers reported no severe cases of cytokine release syndrome or neurotoxicity in the trial.

Maus said it stood out that the treatment worked in patients whose cancer had returned after BCMA-targeted treatment. She also said patients tested showed no immune reaction against TriPRIL.

The study was published in The Lancet. Researchers said its small size and relatively short follow-up mean larger, longer studies are needed to assess how long benefits last and identify less common side effects.

The team is planning a phase 2 trial with more patients and longer follow-up.

Advertisement
Take the quizWhat Kind of Holiday Spender Are You? Take the Black Friday QuizStart →
Advertisement
Most Read
  1. 1U.S. Emergency Alert Test Nov. 17 Is Not a Power Outage
  2. 2DUP Chairman Lord Morrow Loses Wife and Daughter Within Hours in NI
  3. 3NASA’s Curiosity Rover Burst Open a Rock and Found Pure Sulfur
  4. 4Women With Autoimmune Diseases Wait About 4 Years for Diagnosis, Study Finds
  5. 5Stock Market Today: Dow Futures Slip as Nasdaq Futures Climb Before Earnings
Advertisement
Don't Miss

Latest News

All stories →
  1. World · EuropeUK Climate Adviser Warns EV Cuts Put Targets at RiskNov 18
  2. Business · EnergyUK Inflation Rises 3.6% as Energy Costs Add PressureNov 18
  3. World · EuropeNHS England Logs 3,029 Staff Snooping Incidents in Five YearsNov 18
  4. World · United StatesColorado Regulators Face Fuel Chemical Disclosure ChallengeNov 18
  5. Advertisement
  6. WorldHong Kong Hospital Apologizes After Surgeon Removes Both Ovaries by MistakeNov 18
  7. Technology · AIJava Software Vulnerability Found With AI, Oracle Issues PatchNov 18
  8. Lifestyle · Food & HealthVoy Ads Banned Over Claims Linking Symptoms to Low TestosteroneNov 18
  9. Markets · StocksCoinbase (COIN) Stock on Tuesday: Slides 4.02%, Down 32.7% in a MonthNov 18